osteomyelitis, spinal epidural abscess, septic arthritis, brain abscess, and septic pulmonary emboli.
Diagnosis

Clinical Features
Fever or chills are the most sensitive clinical features, associated with positive blood cultures in 60% to 80% of patients. 7, 8 Only 5% of patients with CRBSIs will have a concurrent exit-site or tunnel infection. 9 Other clinical manifestations of CRBSIs include hemodynamic instability, altered mental status, catheter dysfunction, hypothermia, nausea/vomiting, and generalized malaise ( Figure 1 ). In some cases, complications related to a CRBSI may be the first clues to the presence of a CRBSI (see section "Infection Complications").
Clinical Definitions
Several definitions for catheter-related infections are cited in the literature; however, consensus is not attained. 10, 11 In addition to the many technical diagnostic challenges (Table 1) , it is very important to recognize the difference between surveillance definitions for CRBSIs and clinical definitions. Surveillance definitions for CRBSI include all bacteremias that occur in patients with catheters, likely overestimating the true incidence of CRBSIs because not all bacteremias originate from the catheter. Clinical definitions of CRBSIs are those where other sources of infection are excluded by patient examination and review of patient record, and finding of positive catheter tip cultures (if available) with the same organism as that seen on blood cultures. To accurately compare health care facilities' infection rates with each other, and with published data, comparable definitions should be used.
Despite the challenges, there are several commonly used and accepted clinical definitions of catheter-related infections in the literature. The reader can find details of these definitions in the following references: Kidney Disease Outcomes Quality Initiative (KDOQI), 12 Centers for Disease Control and Prevention (CDC), 13 Infectious Diseases Society of America (IDSA), 14 and Public Health Agency of Canada. 15 A summary of these clinical definitions can be found in Table 2 . To illustrate the differences in clinical and surveillance definitions, Table 3 provides the CDC surveillance definitions for primary BSIs associated with intravascular devices.
The IDSA 14 and CDC 13 definitions for exit-site infection and tunnel infection are provided below:
Exit-site infection ( Figure 2 ).
IDSA-Hyperemia, induration, and/or tenderness ≤2 cm from catheter exit site. May be associated with fever and purulent drainage from the exit site. It may or may not be associated with bacteremia. If there is purulent drainage, it should be collected and sent for Gram staining and culture.
CDC-Erythema or induration within 2 cm of the catheter exit site, in the absence of concomitant BSI and without concomitant purulence.
Tunnel infection (Figure 3).
IDSA-Tenderness, hyperemia, and/or induration that extends >2 cm from the exit site and along the subcutaneous tunnel. It may or may not be associated with bacteremia. If there is purulent drainage, it should be collected and sent for Gram staining and culture.
CDC-Tenderness, erythema, or site induration >2 cm from the catheter site along the subcutaneous tract of a tunneled catheter, in the absence of concomitant BSI. 16 There are several risk factors for the development of infection, including conditions of catheter insertion, site of catheter insertion, and duration of use (Table 4) . 6, 17, 18 The most effective strategy for prevention of CRBSIs is reducing the use of catheters. Other basic measures include improved catheter care, good hand hygiene practices, and education for both patients and staff on vascular access care. As catheter use cannot be eliminated, CDC has recommended several core interventions to decrease infections (Table 5) . Several of these recommendations are incorporated in catheter care bundles, which have been shown to reduce catheter-related infections in patients with central venous catheters.
Prevention of Catheter-Related Infections
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Catheter Site Selection
The right internal jugular vein is the preferred initial insertion site for tunneled catheters (see "Catheter Site Selection" section in Clark et al 23 ). Subclavian catheters are avoided if possible due to increased risk of central venous stenosis (see "Risk Factors for Central Vein Stenosis" section in Miller et al 24 ). Femoral catheters have generally been considered less preferable to internal jugular catheters due to concerns of catheter dysfunction and increased risk of infection. However, the Cathedia study randomized 750 patients from 12 different intensive care units to either femoral or internal jugular nontunneled hemodialysis catheter insertion for acute renal replacement therapy (RRT), and showed similar infection rates between femoral and internal jugular catheterization. 25 However, in a prespecified subgroup analysis according to body mass index (BMI), those in the highest BMI tertile (>28.4) had a higher risk of infection with femoral versus internal jugular nontunneled hemodialysis catheters, whereas patients in the lowest BMI tertile (<24.2) had lower risk of infection with femoral versus internal jugular catheters. This suggests that femoral catheters may have a role in this subset of patients requiring dialysis for acute kidney injury. It is unknown whether similar findings would be observed in noncritically ill hemodialysis patients with tunneled catheters. The left internal jugular, external jugular, subclavian, and femoral veins, and transhepatic and translumbar are other sites available for insertion of these catheters.
Maximal Barrier Precautions at the Time of Catheter Insertion
A cap, mask, sterile gown, and sterile gloves should be worn at the time of placing a catheter. The catheter insertion site should be prepped using sterile technique. A sterile full body drape should be used leaving only a small opening at the insertion site. 26 
Dressing Type and Replacement Intervals
There are no definitive recommendations for the optimal dressing or frequency of change for hemodialysis catheters (see "Tunneled Cuffed Catheter Care" section in Clark et al 23 ). The Canadian Society of Nephrology guidelines recommend dressing changes with each hemodialysis treatment. 27 Either sterile gauze or sterile, transparent, semipermeable dressing can be used to cover the exit site. 16 Both patient and environmental factors should be considered when selecting dressing type. Dressings should not be submerged in water. Dressings should be changed when they become damp, loose, soiled, nonocclusive, or nonadherent, and only trained dialysis staff should change catheter dressings.
Antimicrobials/Antiseptic Application to Catheter Exit Site
Chlorhexidine skin preparation has been shown to be superior to povidone-iodine and alcohol in the prevention of catheter-related infection. 28, 29 A solution containing 1% to 2% chlorhexidine gluconate in ≥70% ethyl or isopropyl alcohol (alcoholic chlorhexidine) should be used to cleanse the area. If chlorhexidine is contraindicated (eg, sensitivity, allergy), povidone-iodine 10% in 70% ethanol should be used. The antiseptic solution should be applied using friction, for at least 30 seconds and allow to air-dry without wiping or blotting.
Topical Antimicrobial Application
Antimicrobial application to exit site with dressing changes can reduce catheter-related infections. A meta-analysis by James et al 30 examined whether topical or intraluminal antibiotic instillations compared with no antibiotic therapy reduced CRBSIs in adults undergoing hemodialysis. They showed topical antibiotics, compared with no antibiotic therapy, lowered bacteremia rates (rate ratio [RR]: 0.22, 95% confidence interval [CI]: 0.12-0.40) and exit-site infection rates (RR: 0.17, 95% CI: 0.08-0.38). However, several types of antimicrobial agents or co-intervention were used in the trials, thereby making it difficult to determine the impact of the topical antibiotic alone in reducing infection. Furthermore, many studies were of short duration and important clinical outcomes such as hospitalization and death were not reported.
A Cochrane review of interventions to prevent infectious complications associated with hemodialysis catheters was recently published. 31 It included randomized controlled trials (RCTs) and quasi-RCTs investigating interventions to prevent infection but excluded impregnated catheters and antimicrobial solutions. Ten trials were included in their analysis. Their findings included the following: 
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Associated with a reduction in all-cause mortality (RR: 0.22, 95% CI: 0.07-0.74), but no effect on infection-related mortality. This was based on a single study (Hemodialysis Infection Prevention with Polysporin, HIPPO study), 3 which enrolled 169 hemodialysis patients with a central venous catheter. Patients were randomized to polysporin triple antibiotic ointment or placebo over a 6-month trial. The CDC's Dialysis BSI Prevention Collaborative recommends application of an antibiotic ointment or povidoneiodine ointment to catheter exit sites during dressing changes. 22 However, the practice of antimicrobial ointment application has not been widely adopted, in part due to concerns of development of antimicrobial resistance. Use of antimicrobial agents should be based on local infection rates and practice.
Antimicrobial Locks
Multiple RCTs and meta-analyses have been done assessing the role of antibiotic locks in the prevention of CRBSIs. 30, [32] [33] [34] [35] [36] All meta-analyses have shown a reduction in bacteremia rates with the use of antimicrobial locks. However, catheter lock solutions were sometimes used in conjunction with other preventive measures such as topical antimicrobial ointment, likely impacting findings. Furthermore, many studies had a short duration of follow-up, so long-term benefit or loss of efficacy, development of antimicrobial resistance, or other adverse effects could not be evaluated. Heterogeneity between studies and publication bias was also evident, thereby limiting interpretation and conclusions.
The only study of antibiotic locks in the prevention of CRBSIs that has demonstrated a mortality benefit is an observational study comparing gentamicin-citrate with heparin published in 2014. 37 There were 555 patients (1350 catheters) included in this study, for a total of 84 326 days in the heparin group and 71 192 days in the gentamicin-citrate group. Compared with heparin, gentamicin-citrate was associated with decreased CRBSI rates (0.45 per 1000 catheter days vs 1.68 per 1000 catheter days; RR: 0.23, 95% CI: 0.13-0.38) and mortality (Hazard Ratio, HR: 0.32, 95% CI: 0.14-0.95).
The main concerns with prolonged use of antimicrobial lock solutions are the potential development of antimicrobial resistance and other adverse effects. This has resulted in cautious use of antibiotic locks, highlighting the need for further study in this area with longer follow-up duration, examining clinically important outcomes such as antibiotic resistance, hospitalization, and mortality.
Treatment of Catheter-Related Infection
Exit-Site Infection
Obtain cultures of any drainage from the exit site before administration of antibiotics. Treat empirically with antibiotics to cover gram-positive organisms. Modify the antibiotic regimen once culture and sensitivity results are available. Exit-site infections are typically treated for 7 to 14 days, depending on the microorganism isolated and local practice.
Tunnel Infection
Obtain cultures of any drainage from the exit site and send blood cultures from the catheter. The catheter should always be removed, without exchange over a wire. A new catheter should be inserted at a separate site. Start empiric broadspectrum antibiotics to cover both gram-positive and gramnegative organisms. Modify antibiotic regimen when culture and sensitivity results are available. Tunnel infections, in the absence of a concurrent CRBSI, are typically treated for 10 to 14 days, depending on the microorganism isolated and local practice. If a CRBSI is also present, then duration of therapy will be determined by the management of the CRBSI (see section "Definitive management").
Catheter-Related Bloodstream Infection
Empiric management. Blood cultures should be sent from the catheter, dialysis circuit, and peripheral sites if possible. A recent prospective study of 178 suspected CRBSIs in hemodialysis patients showed that blood culture results are the most sensitive, specific, and accurate for diagnosis when taken from the hemodialysis circuit and the venous catheter hub, compared with any combination with peripheral vein cultures. 38 Broad-spectrum antibiotics should be initiated to cover both gram-positive and gram-negative organisms. 14 Antibiotics should generally cover methicillin-resistant S aureus (MRSA) and Pseudomonas but are also dictated by local infection rates, dialysis center policies, and center-specific antimicrobial resistance patterns. Following initiation of empiric antibiotic therapy, it is crucial that culture sensitivity data are followed up in a timely manner, so that the most appropriate antibiotics based on sensitivity results can be used.
Definitive management. Definitive management of CRBSIs must be tailored to the clinical presentation of the patient, the microorganism isolated, and vascular access options of the patient. For example, management of the patient with septic shock secondary to MRSA CRBSI will differ from that of a hemodynamically stable patient presenting with a fever and found to have coagulase-negative staphylococcus. Treatment can be categorized into 3 groups: systemic antibiotics, antimicrobial locking (instillation) solutions, and catheter management. Comparison of treatment strategies is very challenging because many studies are observational design with different methodologies, and have differences in CRBSI definitions, as well as different outcome measures.
Systemic antibiotics
• • All patients with a CRBSI should receive systemic antibiotics, which will typically be administered for 2 to 6 weeks depending on the microorganism, clinical presentation, and complications. • • Final decision on specific antibiotic agent(s) is dependent on final blood culture result and sensitivities, and whether or not patient has any allergies. If methicillinsensitive S aureus (MSSA) infection is isolated, cefazolin is the preferred choice over vancomycin because it is associated with decreased hospitalization and death secondary to infection.
39
• • Ease of administration is also a factor, ideally choosing agents that can be given to patients 3 times weekly for patients receiving conventional thrice weekly dialysis. • • Drug dose and timing vary for those who are not on conventional thrice weekly dialysis (eg, short daily or nocturnal dialysis).
Antibiotic locks • • May be used as adjunctive therapy to systemic antibiotics. • • There are no randomized trials on the role of antibiotic locks in the treatment of CRBSIs, but several observational studies have shown similar eradication of bacteremia in patients treated with systemic antibiotics plus antibiotic lock compared with systemic antibiotics and catheter exchange or removal.
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• • A recent systematic review and meta-analysis of hemodialysis patients with tunneled dialysis catheters, with a CRBSI, compared 3 treatment protocols for CRBSIs: (1) systemic antibiotics alone, (2) systemic antibiotics plus antibiotic lock (catheter not removed), and (3) systemic antibiotics plus guidewire exchange. 41 It included 28 retrospective and prospective studies, with a total of 1596 patients. Patients treated with systemic antibiotics and antibiotic lock had similar cure rates to those treated with systemic antibiotics and guidewire exchange, and both were superior to the rates obtained when antibiotics were used alone. Recurrence of infection with the same organism was not different between the systemic antibiotics plus antibiotic lock group and the systemic antibiotics plus guidewire exchange but was much higher in patients treated with systemic antibiotics alone, which further supports the practice to use an antibiotic lock or guidewire exchange in conjunction with systemic antibiotics. • • Antibiotic locks should be used when immediate catheter removal is not possible and when catheter salvage attempted. 
Catheter removal with replacement in new site
Infection Complications
Infection complications are thought to occur in ~15 -40% of CRBSIs. 6 These are most common for S aureus infections, with endocarditis being the most common. Other complications include vertebral osteomyelitis or discitis (2%-15%), and less commonly, spinal epidural abscess, septic arthritis, and septic pulmonary emboli. Mortality rates are high: Reports in the literature vary between 6% and 34% in all cases of CRBSI. Mortality is highest with S aureus infection complicated by metastatic complications, associated with 30% to 50% of mortality in these patients. of S aureus bacteremias in hemodialysis patients, significantly higher than in S aureus infection in the general population. 45 Next most common organisms are coagulase-negative staphylococci, enterococci, and viridans group streptococci.
• • Consider transthoracic echocardiography in all patients with S aureus CRBSIs. • • Associated with mortality rates of 30% to 50%. [42] [43] [44] • • Requires minimum 6 weeks' intravenous antibiotic therapy. Spinal Epidural Abscess
Vertebral Osteomyelitis or Discitis
• • Most common symptoms are back pain, fever, and weakness. • • MRI is the best diagnostic modality.
• • Requires minimum 6 weeks' antibiotic therapy, and all patients should have neurosurgical evaluation. 
Septic Arthritis
Infection Surveillance Program
An infection surveillance program that can facilitate identification of catheter-related infections and lead to timely intervention is key to monitoring catheter-related infections and their complications. Several studies have demonstrated the clinical benefits of an active surveillance program. 46, 47 Surveillance programs require dedicated teams and resources, and should monitor outcome measures including CRBSI rates, hospitalizations, and death. A multidisciplinary team of infection control personnel plays a critical role in preventing infections and improving outcomes. 48 Effective surveillance programs should continuously monitor for opportunities for improvement, and engage staff and patients in the implementation and maintenance of strategies to prevent CRBSIs. A CRBSI 
Summary
•• CRBSIs are a major cause of hospitalization and mortality in hemodialysis patients. •• Prevention is key! The CDC outlines 9 core preventive measures to reduce CRBSIs, including maximal barrier precautions with catheter insertion and catheter care, topical antibiotics, education, and surveillance. •• Gram-positive organisms are responsible for most CRBSIs, with S aureus and coagulase-negative staphylococci comprising 40% to 80%. •• S aureus bacteremia is associated with 30% to 50% mortality in hemodialysis patients, and most likely to cause metastatic complications. •• Treatment strategies for CRBSIs can be categorized into systemic antibiotics, antibiotics locks, and catheter management. •• CRBSI management decisions depend on clinical presentation of the patient, microorganism isolated, and vascular access options of the patient.
•• All CRBSIs require a minimum 2 to 3 weeks' systemic antibiotic therapy. 
•• S aureus
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